Lexeo director granted 35,000 stock options

Lexeo Therapeutics, Inc. director Mette Kirstine Agger received a grant of stock options covering 35,000 shares of common stock.

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. director Mette Kirstine Agger received a grant of stock options covering 35,000 shares of common stock. The options have an exercise price of $4.70 per share and expire on June 24, 2036. According to the vesting terms, all 35,000 underlying shares will vest and become exercisable on the earlier of one year after the grant date or the next annual meeting of stockholders, as long as she continues in service through that date. After this grant, she holds stock options for 35,000 shares directly.

Insider Trade Summary

Grant/Award: 35,000 shares

Grant/Award 1 txn

Insider Agger Mette Kirstine

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	35,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 35,000 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.

Key Figures

Option grant size: 35,000 options Exercise price: $4.70 per share Underlying shares: 35,000 shares +2 more

5 metrics

Option grant size 35,000 options Stock Option (right to buy) covering common stock

Exercise price $4.70 per share Exercise price of the granted stock options

Underlying shares 35,000 shares Common stock underlying the option grant

Expiration date June 24, 2036 Option term endpoint for this grant

Post-grant option holdings 35,000 options Total options held following this transaction

Key Terms

Stock Option (right to buy), Common Stock, exercise price, vest

4 terms

Stock Option (right to buy) financial

"Stock Option (right to buy)"

Common Stock financial

"underlying_security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercise price financial

"conversion_or_exercise_price": "4.7000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"100% of the shares underlying the option shall vest, and become exercisable"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Lexeo Therapeutics (LXEO) report for Mette Kirstine Agger?

Lexeo Therapeutics reported that director Mette Kirstine Agger received a grant of stock options covering 35,000 shares of common stock. The award is a compensation-related grant, not an open-market share purchase or sale, and is structured as a right to buy shares in the future.

How many Lexeo Therapeutics (LXEO) shares are covered by the new stock options?

The new stock option grant covers 35,000 shares of Lexeo Therapeutics common stock. These are derivative securities, giving the director the right to buy shares later if she chooses to exercise, subject to vesting and the specified option terms in the award.

What is the exercise price of the new Lexeo Therapeutics (LXEO) stock options?

The stock options granted to the director have an exercise price of $4.70 per share. This means she can buy Lexeo common stock at $4.70 once the options vest, regardless of the market price at that time, until the options expire in the future.

When do the Lexeo Therapeutics (LXEO) stock options granted to the director vest?

All 35,000 shares underlying the options vest on the earlier of one year after the grant date or the next annual stockholder meeting. Vesting is conditional on the director’s continuous service with Lexeo Therapeutics through the applicable vesting date described in the award terms.

When do the newly granted Lexeo Therapeutics (LXEO) stock options expire?

The granted stock options expire on June 24, 2036. After that expiration date, the director can no longer exercise the options to buy Lexeo common stock, even if they were vested and otherwise exercisable before the expiration of the option term.

Is the Lexeo Therapeutics (LXEO) transaction a stock purchase or sale on the market?

This transaction is not a market purchase or sale of Lexeo shares. It is a grant of stock options as compensation, classified as a derivative security. No shares were bought or sold in the open market as part of this specific Form 4 transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Agger Mette Kirstine

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.7	06/25/2026		A		35,000		(1)	06/24/2036	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.

	/s/ Youjin Choi, Attorney-in-Fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)